BioStem Technologies to Present at Needham Healthcare Conference, Highlighting Regenerative Medicine Advancements

BioStem Technologies Inc., a leading regenerative medicine company focused on perinatal tissue allograft products, announced that company management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET, with live and archived webcasts available through the company's investor relations section at https://ir.biostemtechnologies.com. This conference appearance provides BioStem with a platform to discuss its growing portfolio of regenerative medicine products and proprietary processing technologies that are designed to optimize tissue preservation for clinical applications.

The company's presentation at this prominent healthcare conference matters because it represents an opportunity to communicate directly with investors and industry stakeholders about advancements in regenerative medicine. BioStem's focus on perinatal tissue allografts addresses significant clinical needs across multiple medical specialties, and conference participation allows the company to demonstrate progress in this rapidly evolving field. The implications extend beyond investor relations to potential clinical adoption, as successful communication of technological advantages could accelerate acceptance of BioStem's products among healthcare providers.

BioStem leverages proprietary processing technologies including BioRetain®, CryoTek® and SteriTek® that are designed to preserve the natural properties of perinatal tissues. These technologies support the company's portfolio of quality brands including Neox®, Clarix®, VENDAJE® and American Amnion™ product lines. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, with systems established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. This regulatory compliance framework provides important validation of the company's approach to tissue processing and product development.

The importance of BioStem's conference presentation lies in the broader context of regenerative medicine innovation. As the company expands its clinical research initiatives and national commercial footprint, effective communication of its technological advantages becomes increasingly critical. The Needham Healthcare Conference represents a significant venue for such communication, bringing together industry leaders, investors, and analysts focused on healthcare innovation. BioStem's participation signals ongoing commitment to advancing regenerative medicine solutions that address unmet clinical needs across various medical specialties.

For those interested in following company developments, additional information is available at https://biostemtechnologies.com. The company maintains an investor relations section at https://ir.biostemtechnologies.com where conference materials and updates are typically posted. BioStem's presentation at the Needham conference represents an important milestone in communicating the company's progress in developing advanced allograft solutions derived from perinatal tissue, with implications for both clinical practice and investment consideration in the regenerative medicine sector.